je.st
news
Compugen Extends Discovery Capabilities To Additional Immunomodulatory Proteins
2014-07-30 10:01:01| drugdiscoveryonline Home Page
Compugen Ltd. recently announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the Company’s Pipeline Program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints
Tags: additional
discovery
capabilities
proteins
Category:Biotechnology and Pharmaceuticals